Daniel J. Hogan

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

William P. Accomando, T. Mikkelsen, T. Cloughesy, 2018, Neuro-oncology.

Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients

Jay-Jiguang Zhu, A. Das, H. Gruber, 2018, Clinical Cancer Research.

Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma

Ash A. Alizadeh, Aliz R. Rao, Aaron M. Newman, 2020, Clinical Cancer Research.

MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.

M. Hanna, D. Ostertag, O. Diago, 2016, Epigenomics.

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

D. Jolly, D. Ostertag, O. Diago, 2016, Human gene therapy methods.

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

T. Mikkelsen, T. Cloughesy, L. Liau, 2016, Science Translational Medicine.